Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma - Migden, M R; Berkin, C; Chang, A L (Skin J Cutan Med, 2018)
et al.